Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director · CEO and President | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,720 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Exercise / conversion · Acquired 12,517 · Balance 130,720 F1: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2029-08-15 | Direct | 61,887 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Exercise / conversion · Disposed 12,517 · Balance 61,887 F1: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. F3: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is August 15, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 191,388 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 191,388 F2: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.
F2: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
F3: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is August 15, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 22:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 12,517 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001193125-26-382208 · ownership.xml · derivative · entry 3 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,887 Underlying: Common Stock · 12,517 shares Expires 2029-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. F3 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is August 15, 2019. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 22:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 12,517 | $3.47 | $43,433.99 |
DisclosureSEC source: 0001193125-26-382208 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,361 | $11.93 | $16,236.73 |
DisclosureSEC source: 0001193125-26-294474 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,203 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:43 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001193125-26-292932 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 20,000 shares Expires 2027-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F4 · derivative.exercise_date: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:43 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 20,000 | $19.38 | $387,600.00 |
DisclosureSEC source: 0001193125-26-292932 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,842 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $19.15 to $19.54. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:43 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 20,000 | $2.50 | $50,000.00 |
DisclosureSEC source: 0001193125-26-292932 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001193125-26-277503 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 60,000 shares Expires 2027-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F5 · derivative.exercise_date: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 1,843 | $17.94 | $33,063.42 |
DisclosureSEC source: 0001193125-26-277503 · ownership.xml · nonDerivative · entry 3 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 191,388 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.75 to $18.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 60,000 | $17.79 | $1,067,400.00 |
DisclosureSEC source: 0001193125-26-277503 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,842 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.35 to $18.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 60,000 | $2.50 | $150,000.00 |
DisclosureSEC source: 0001193125-26-277503 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:23 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 20,942 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001193125-26-117695 · ownership.xml · derivative · entry 3 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,414 Underlying: Common Stock · 20,942 shares Expires 2030-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. F3 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is July 9, 2020. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:23 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 20,942 | $3.24 | $67,852.08 |
DisclosureSEC source: 0001193125-26-117695 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 84,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-108083 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,828 Underlying: Common Stock · 84,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 43,161 | $11.53 | $497,646.33 |
DisclosureSEC source: 0001193125-26-108083 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,900 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 84,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-108083 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 47,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-100364 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 22,709 | $10.00 | $227,090.00 |
DisclosureSEC source: 0001193125-26-100364 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,232 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 47,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-100364 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:48 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 26,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-094153 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,273 Underlying: Common Stock · 26,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:48 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 9,533 | $8.84 | $84,271.72 |
DisclosureSEC source: 0001193125-26-094153 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,534 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:48 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 26,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-094153 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 19,951 | $15.17 | $302,656.67 |
DisclosureSEC source: 0001193125-26-076586 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 193,231 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.15 to $15.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Reflects 934 shares previously owned by the Joseph M. Burnett Trust dated 10/20/2022 (the "Trust") which were transferred to the Reporting Person as direct ownership on February 6, 2026. F4 · ownership.nature: These shares are owned directly by the Trust and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 147,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059357 · ownership.xml · derivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,275 Underlying: Common Stock · 147,275 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:27 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 2,943 | $15.57 | $45,822.51 |
DisclosureSEC source: 0001193125-26-024544 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 214,116 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.23 to $15.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 22:00 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001193125-26-011866 · ownership.xml · derivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 20,000 shares Expires 2027-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F4 · derivative.exercise_date: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 22:00 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 20,000 | $16.12 | $322,400.00 |
DisclosureSEC source: 0001193125-26-011866 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,565 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.88 to $16.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 22:00 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 20,000 | $2.50 | $50,000.00 |
DisclosureSEC source: 0001193125-26-011866 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:49 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 254 | $9.57 | $2,430.78 |
DisclosureSEC source: 0001193125-26-002949 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,565 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 300 | $29.21 | $8,763.00 |
DisclosureSEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 4 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 217,059 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 1,981 | $28.64 | $56,735.84 |
DisclosureSEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 3 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 217,359 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $28.08 to $29.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 6,599 | $27.64 | $182,396.36 |
DisclosureSEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 219,340 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $27.08 to $28.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 17,583 | $26.51 | $466,125.33 |
DisclosureSEC source: 0001193125-25-239077 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 225,939 F1 · kind: The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $26.07 to $27.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 21:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,424 | $10.15 | $14,453.60 |
DisclosureSEC source: 0000950170-25-093159 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,311 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 23:11 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 15,476 | $13.29 | $205,676.04 |
DisclosureSEC source: 0000950170-25-085700 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,887 F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 01:50 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | SaleCommon Stock | 21,247 | $13.29 | $282,372.63 |
DisclosureSEC source: 0000950170-25-085074 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 243,522 F1 · kind: This sale of shares is incident to the net share settlement of 21,247 shares which vested on March 6, 2025 under a restricted stock unit granted to the reporting person on March 6, 2023. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $13.20 to $13.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 42,414 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-039492 · ownership.xml · derivative · entry 3 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,657 Underlying: Common Stock · 42,414 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 23,405 | $13.18 | $308,477.90 |
DisclosureSEC source: 0000950170-25-039492 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,132 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 42,414 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-039492 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:44 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 47,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036671 · ownership.xml · derivative · entry 3 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,407 Underlying: Common Stock · 47,407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:44 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 26,160 | $13.19 | $345,050.40 |
DisclosureSEC source: 0000950170-25-036671 · ownership.xml · nonDerivative · entry 2 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,123 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:44 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 47,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036671 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 132,841 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032365 · ownership.xml · derivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,841 Underlying: Common Stock · 132,841 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 3, 2026; (ii) 40% of the total shares on March 3, 2027; and (iii) 40% of the total shares on March 3, 2028. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 3, 2026; (ii) 40% of the total shares on March 3, 2027; and (iii) 40% of the total shares on March 3, 2028. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:19 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 251 | $4.53 | $1,137.03 |
DisclosureSEC source: 0000950170-25-001356 · ownership.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,876 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 20:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 3,236 | $11.26 | $36,437.36 |
DisclosureSEC source: 0001285550-24-000102 · wk-form4_1724271484.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,625 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:25 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,500 | $4.58 | $16,030.00 |
DisclosureSEC source: 0001285550-24-000089 · wk-form4_1719955526.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,861 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:31 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 14,003 | $5.74 | $80,377.22 |
DisclosureSEC source: 0001285550-24-000080 · wk-form4_1718148703.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,361 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:38 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 212,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000073 · wk-form4_1716410286.xml · derivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,071 Underlying: Common Stock · 212,071 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 12, 2025; (ii) 40% of the total shares on March 12, 2026; and (iii) 40% of the total shares on March 12, 2027. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 12, 2025; (ii) 40% of the total shares on March 12, 2026; and (iii) 40% of the total shares on March 12, 2027. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:39 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 23,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000023 · wk-form4_1709933958.xml · derivative · entry 3 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,814 Underlying: Common Stock · 23,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:39 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 11,066 | $6.24 | $69,051.84 |
DisclosureSEC source: 0001285550-24-000023 · wk-form4_1709933958.xml · nonDerivative · entry 2 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,364 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:39 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 23,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000023 · wk-form4_1709933958.xml · nonDerivative · entry 1 BURNETT JOSEPH MICHAEL · CIK 0001721010 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.